Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Post-transplant lymphoproliferative disorder.

Alison W Loren1, Donald E Tsai

  • 1Division of Hematology/Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

Clinics in Chest Medicine
|November 3, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

The Lancet. Haematology·2026
Same author

WITHDRAWN: Correction to Chronic graft-versus-host disease. Part I: Epidemiology, pathogenesis, and clinical manifestations [Journal of the American Academy of Dermatology 2024 Jan;90(1)1-16].

Journal of the American Academy of Dermatology·2026
Same author

WITHDRAWN: Correction to Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management [Journal of the American Academy of Dermatology 2024 Jan;90(1)19-36].

Journal of the American Academy of Dermatology·2026
Same author

Discordance in Treatment Response Assessment Between Clinicians and Patients With Skin Chronic Graft-vs-Host Disease.

JAMA dermatology·2026
Same author

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Blood advances·2026
Same author

Management of Cancer During Pregnancy: ASCO Guideline.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same journal

Pneumonia Reimagined: Host, Microbe, and the Shifting Landscape of Disease.

Clinics in chest medicine·2026
Same journal

Advocacy in Pneumonia.

Clinics in chest medicine·2026
Same journal

Vaccines Against Pneumonia: Current Updates.

Clinics in chest medicine·2026
Same journal

Non-antibiotic Treatments for Pneumonia: Host-Directed Therapies, Next-Steps and Future Directions.

Clinics in chest medicine·2026
Same journal

Customizing Antibiotic Treatment for Pneumonia: Can We Have a Single Unified Algorithm for All Types of Pneumonia?

Clinics in chest medicine·2026
Same journal

The Role of Complex Digital Interventions to Improve Pneumonia Care.

Clinics in chest medicine·2026
See all related articles

Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after transplantation. Early detection and new therapies, including immune modulation and cellular treatments, significantly improve cure rates for this condition.

Area of Science:

  • Immunology
  • Oncology
  • Transplantation Medicine

Background:

  • Post-transplant lymphoproliferative disorder (PTLD) is a significant complication following solid organ and hematopoietic stem cell transplantation.
  • PTLD involves the proliferation of lymphocytes, typically B cells, and can range from polyclonal to monoclonal.
  • A high index of suspicion is crucial for prompt diagnosis.

Purpose of the Study:

  • To summarize the current understanding of Post-transplant lymphoproliferative disorder (PTLD).
  • To highlight the importance of early diagnosis in managing PTLD.
  • To review the advancements in therapeutic strategies for PTLD.

Main Methods:

  • Literature review of PTLD diagnosis and treatment.
  • Analysis of current therapeutic approaches including immune modulation, monoclonal antibodies, and cellular therapy.

Related Experiment Videos

  • Synthesis of data on improved cure rates.

    • Main Results:

    • PTLD is an increasing concern in transplant recipients.
    • Effective therapies have been developed, including reduction in immunosuppression, targeted antibody treatments, and cellular therapies.
    • These advancements have led to dramatically improved cure rates for PTLD.

    Conclusions:

    • Prompt diagnosis of PTLD is essential for successful management.
    • Modern therapeutic options have significantly enhanced patient outcomes.
    • PTLD, once a devastating disease, is now more manageable with advanced treatments.